<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526174</url>
  </required_header>
  <id_info>
    <org_study_id>HRI-002</org_study_id>
    <secondary_id>TNFalpha</secondary_id>
    <nct_id>NCT01526174</nct_id>
  </id_info>
  <brief_title>Intratympanic Injection for Autoimmune Inner Ear Disease</brief_title>
  <acronym>AIED</acronym>
  <official_title>Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>House Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Services, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>House Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to conduct an open-label intratympanic injection proof-of-concept&#xD;
      trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients&#xD;
      with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm&#xD;
      approach. First, the investigators propose to dose 3 individual subjects with a single&#xD;
      intratympanic injection of golimumab and follow each for 30 days, closely examining them for&#xD;
      adverse events. If there are no serious adverse events, with FDA approval, the investigators&#xD;
      propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    House Research no longer conducting research.&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pure-tone threshold change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in pure-tone threshold from baseline to 6 week after initiation of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autoimmune Inner Ear Disease</condition>
  <arm_group>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine safety of intratympanic injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy evaluation of 4 intratympanic injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections</description>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_label>Second Arm</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of autoimmune inner ear disease (AIED) by the principal investigator&#xD;
&#xD;
          -  Idiopathic, bilateral sensorineural hearing loss&#xD;
&#xD;
          -  History of, or audiograms showing, rapid progression of hearing loss&#xD;
&#xD;
          -  Bilateral loss of at least 30 dB in one or more frequencies (0.25 - 6 kHz)&#xD;
&#xD;
          -  Hearing responsive on high-dose oral steroids and steroid-dependent, as determined by&#xD;
             history and the principal investigator. The subject can be taking oral steroid, at the&#xD;
             maintenance level, if enrolled in the First Arm and, if enrolled in the Second Arm,&#xD;
             will begin taper after the first injection.&#xD;
&#xD;
          -  Provided written informed consent for participation in the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive MRI for vestibular schwannoma&#xD;
&#xD;
          -  Positive FTA (syphilis)&#xD;
&#xD;
          -  Significant middle ear disease (e.g., otitis media)&#xD;
&#xD;
          -  Positive blood test for Lyme disease&#xD;
&#xD;
          -  Positive tuberculosis test&#xD;
&#xD;
          -  Concurrent or past treatment or use of medications and/or substances known to cause&#xD;
             ototoxicity(for example, aminoglycosides [e.g., gentamicin], cisplatin, loop&#xD;
             diuretics, Yorgason et al., 2006)&#xD;
&#xD;
          -  Known adverse reaction to golimumab, adalimumab, etanercept, infliximab, rituximab,&#xD;
             ustekinumab, or other biologic immunomodulators&#xD;
&#xD;
          -  Concurrent (within the past 3 months prior to enrollment) live viral intranasal&#xD;
             vaccine (flu)&#xD;
&#xD;
          -  Positive test for HIV&#xD;
&#xD;
          -  Positive test for Hepatitis B and C&#xD;
&#xD;
          -  Presence of a demyelinating disease, such as multiple sclerosis&#xD;
&#xD;
          -  Women of childbearing potential only: Positive serum pregnancy test prior to the&#xD;
             only/first injection&#xD;
&#xD;
          -  Active infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Derebery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Research Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune</keyword>
  <keyword>hearing loss</keyword>
  <keyword>bilateral hearing loss</keyword>
  <keyword>steroid-dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Labyrinth Diseases</mesh_term>
    <mesh_term>Labyrinthitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Golimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

